Document:

Unassociated Document

    SALE
      AND PURCHASE AGREEMENT

    

    

    THIS
      AGREEMENT
      is made
      on December 1, 2006

    

    BETWEEN:

    

    
      	(1)	
              NEW
                PASSION INVESTMENTS LIMITED,
                a
                company incorporated under the laws of British Virgin Islands of
                TrustNet
                Chambers, P.O. Box 3444, Road Town, Tortola, British Virgin Islands
                (the
                “Seller”);
                and

            

    

    

    
      	(2)	
              INFOSCIENCE
                MEDIA LIMITED,
                a
                company incorporated under the laws of Hong Kong of 5/F,
                QPL Industrial Building, 126-140 Texaco Road, Tsuen Wan, Hong
                Kong (the
                “Buyer”).

            

    

    

    

    WHEREAS:
      

    

    
      	
              (A)

            	
              InfoScience
                Holdings Limited (the "Company")
                is a limited liability company incorporated under the laws of Hong
                Kong
                (company number: 884147) and at the date hereof, the Seller is the
                legal
                and beneficial owner of 100 shares of HK$1 each in the Company,
                representing the entire issued share capital of the Company (the
                “Sale
                Shares”).

            

    

    

    
      	
              (B)

            	
              The
                Seller has agreed to sell, and the Buyer has agreed to buy, the Sale
                Shares subject to the terms and conditions contained
                herein.

            

    

    

    

    IT
      IS HEREBY AGREED
      as
      follows:

    

    
      	1.	
              SALE
                AND PURCHASE

            

    

    

    
      	
              1.1

            	
              The
                Seller hereby sells to the Buyer and the Buyer hereby purchases from
                the
                Seller the Sale Shares at the transfer price of HK$1.00 in
                cash.

            

    

    

    
      	
              1.2

            	
              Completion
                of the sale and purchase of the Sale Shares under Clause 1.1 above
                shall
                take place immediately upon execution of this Agreement and at which
                all
                (but not part) of the following business shall be simultaneously
                transacted: 

            

    

    

    
      	 	
              (a)

            	
              the
                Seller shall deliver to the Buyer originals of the bought and sold
                notes
                and instrument(s) of transfer in respect of the Sale Shares duly
                executed
                by the Seller; (ii) share certificate(s) in respect of the Sale Shares;
                and

            

    

    

    
      	 	
              (b)

            	
              the
                Buyer pay to the Seller HK$1.00 in
                cash.

            

    

    
      	 	 	 

    

    

    
      	2.	
              WARRANTIES

            

    

    

    
      	2.1	
              The
                Seller undertakes and
                warrants with the Buyer that
                the Sale Shares shall be sold to the Buyer free
                from all claims, charges, liens, encumbrances, equities and third
                party
                rights and together with all rights attached thereto and all dividends
                and
                distributions declared, paid or made in respect thereof immediately
                on and
                after the date hereof.

            

    

    

    
      	
              2.2

            	
              The
                Seller hereby agrees with the Buyer that upon demand, it shall, in
                relation to any liabilities (both actual and contingent) arising
                from or
                in connection with the Sale Shares, fully and effectually indemnify
                and at
                all times keep fully and effectually indemnified the Buyer from and
                against all liabilities suffered by the Buyer or any claims or demands
                made by any third party against the Buyer, including without limitation
                any and all costs (including all legal costs), expenses or other
                liabilities which the Buyer may incur or suffer in connection
                therewith.

            

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	
              3.

            	
              MISCELLANEOUS

            

    

    

    
      	
              3.1

            	
              Upon
                and after completion under Clause 1.2, the Seller shall do and execute
                or
                procure to be done and executed all other necessary acts, deeds,
                documents
                and things within their power to give effect to this Agreement and
                to
                ensure that the Sale Shares are registered in the Company’s register of
                members in the name of the Buyer (or its
                nominee).

            

    

    

    
      	
              3.2

            	
              All
                stamp duty payable in respect of the carrying into effect of this
                Agreement shall be borne by the Seller and the Buyer
                equally.

            

    

    

    
      	
              3.3

            	
              The
                invalidity, illegality or unenforceability of any provision of this
                Agreement shall not affect the continuation in force of the remainder
                of
                this Agreement.

            

    

    

    
      	
              3.4

            	
              This
                Agreement constitutes the entire agreement in relation to the subject
                matter contained herein. No variation of this Agreement or of any
                of the
                documents in the agreed form shall be valid unless it is in writing
                and
                signed by or on behalf of each of the parties
                hereto.

            

    

    

    
      	
              3.5

            	
              This
                Agreement shall be governed by and construed accordance with the
                laws of
                Hong Kong and the parties hereto agree to submit to the non-exclusive
                jurisdiction of the courts of Hong
                Kong.

            

    

     

     

    IN
      WITNESS
      whereof
      the parties hereto have executed this Agreement the day and year first above
      written.

    

    

      
        	
                SIGNED
                  by

              	
                )

              
	
                for
                  and on behalf of

              	
                )

              
	
                NEW
                  PASSION INVESTMENTS LIMITED

              	
                )

              
	
                in
                  the presence of:

              	
                )

              

      

    

    

    

      
        	
                SIGNED
                  by

              	
                )

              
	
                for
                  and on behalf of 

              	
                )

              
	
                INFOSCIENCE
                  MEDIA LIMITED

              	
                )

              
	
                in
                  the presence of:

              	
                )

              

      

    

    

    
      
         

      

      
        2Unassociated Document

    

    OMNIBUS
      AMENDMENT AND CONSENT 

    

    OMNIBUS
      AMENDMENT AND CONSENT EFFECTIVE AS OF March 30, 2007 (this “Omnibus
      Amendment and Consent”)
      by and
      among Acura Pharmaceuticals, Inc. (the “Company”),
      and
      Acura Pharmaceutical Technologies, Inc. and the following lenders (“Lenders”):
      Galen
      Partners III, L.P. (as agent for the other lenders (“Agent”)
      and as
      a lender itself), Galen Partners International, III, L.P., Galen Employee Fund
      III, L.P., Care Capital Offshore Investments II, LP, Care Capital Investments
      II, LP, Essex Woodlands Health Ventures V, L.P. (the foregoing Lenders, being
      the “VC
      Lenders”),
      Dennis
      Adams, George E. Boudreau, Michael Weisbrot, Susan Weisbrot; and the following
      persons with respect to Sections 5, 6, 7, and 8: John E. Heppe Jr. and Peter
      Steiglitz (“Additional
      Watson Holders”).

    

    Capitalized
      terms used herein and not defined herein have the meanings set forth in the
      Subordination Agreement dated as of January 31, 2006 among the Lenders, the
      Company and others (the “Subordination
      Agreement”).

    

    R
      E C I T A L S

    

    WHEREAS
      the
      Company and one or more Lenders have entered into the June 2005 Loan Agreement,
      the September 2005 Loan Agreement, the November 2005 Loan Agreement and the
      January 2006 Loan Agreement (collectively, the “Loan
      Agreements”)
      and
      such other agreements, notes and instruments executed in connection with such
      loan agreements (collectively, the “Loan
      Documents”);
      and

    

    WHEREAS,
      the
      Company and certain Lenders and the Additional Watson Holders are parties to
      the
      Watson Note (as defined in the Subordination Agreement); and

    

    WHEREAS,
      the
      loans extended pursuant to the Loan Agreements are due to mature on March 31,
      2007 (the “Original
      Maturity Date”);
      

    

    WHEREAS,
      pursuant
      to Section 1(a) of the Omnibus Amendment dated August 16, 2006 among the parties
      hereto (the “August
      2006 Omnibus Amendment”),
      Section 5.12 was added to each Loan Agreement to grant the Lenders the right
      to
      convert their Notes under certain circumstances into equity securities of the
      Company (the “August
      2006 Rollover Right”);

    

    WHEREAS,
      pursuant
      to Section 1(a) of the Omnibus Amendment dated November 30, 2006 among the
      parties hereto (the “November
      2006 Omnibus Amendment”),
      Section 5.12 of each Loan Agreement was amended and restated to grant the
      Lenders a the right to convert their Notes under certain circumstances into
      equity securities of the Company (the “November
      2006 Rollover Right”);

    

    WHEREAS,
      the
      Company and the Lenders wish to extend the Original Maturity Date, amend and
      restate in its entirety the November 2006 Rollover Right as provided herein
      modified and provide for additional bridge loan commitments by the VC
      Lenders.

    

    NOW,
      THEREFORE,
      in
      consideration of the mutual covenants herein contained, the parties mutually
      agree as follows:

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    

    1.
       Amendments:

    

    
      	(a)  	
              The
                January 2006 Loan Agreement is amended by adding thereto Schedule
                1.3A
                attached hereto and by deleting Section 1.1 in its entirety and replacing
                same with the following:

            

    

    

     

    “1.1
      TERM LOAN

     

    On
      the terms and subject to the conditions of this Agreement, each Lender severally
      agrees to make to the Company on the Closing Date a term loan (each, a
“Loan”)
      in
      a principal amount equal to such Lender’s initial Commitment. The Lenders shall
      make additional Loans commencing November 2006, as set forth in Section 1.3,
      and
      may, in their sole and absolute discretion, make additional Loans to the Company
      as provided in Section 1.3 hereof. The Company and the Lenders acknowledge
      and
      agree that no Lender is under any obligation to make any Loan in excess of
      its
      respective Commitment. No amounts paid or prepaid with respect to any Loan
      may
      be reborrowed.”

     

    ;and
      by
      amending and restating the definition of Commitment in Article XVI as
      follows;

     

    ““Commitment”
      means, with respect to each Lender, the commitment of such Lender to make such
      Loan hereunder. The initial amount of the Commitment of each of Essex, Care
      Capital and Galen is set forth opposite its signature hereto. The additional
      mandatory Commitments of the Lenders are set forth in Section 1.3. The
      Commitment of each Additional Lender and/or any additional Commitment of Essex,
      Care Capital and/or Galen will be set forth opposite its signature on the
      Joinder Agreement to which it is a party.”

     

    ;
      and by
      replacing Section 1.3 thereof with the following 

     

    “1.3 CLOSING

     

    The
      initial closing (the “Closing”)
      at
      which the Loans from Essex, Care Capital and Galen shall be disbursed to the
      Company will take place at the offices of St. John & Wayne, L.L.C., Two Penn
      Plaza East, Newark, New Jersey 07105 upon the satisfaction of the conditions
      to
      Closing set forth in this Agreement on the date hereof, or such other place,
      time and date as shall be mutually agreed to by the Company and the Lenders.
      Each Lender agrees to fund additional Loans (“Mandatory Loans”) upon the
      Company’s written request during the months and in the percentage of the monthly
      amount specified next to each Lender’s name on Schedule 1.3 attached hereto and
      on Schedule 1.3A attached hereto. The Company will provide each Lender at least
      ten days notice of the date of the Closing of a Mandatory Loan (which date
      shall
      be binding on all parties), and the amount of Lender’s funding Commitment (based
      on the Lender’s commitment percentage set forth on Schedule 1.3 and Schedule
      1.3A). Any amounts not borrowed by the Company during any month may be borrowed
      by the Company from the Lenders (and will be funded by the Lenders according
      to
      each Lender’s commitment percentage) in succeeding months until the earlier of
      (i) the date advanced to the Company under this Agreement, or (ii) September
      30,
      2007. The Company and the Lenders acknowledge and agree that additional Loans
      (“Non-Mandatory Loans”) may be funded to the Company by any one or more of
      Galen, Care Capital, Essex and any Additional Lender pursuant to the terms
      of
      this Agreement on one or more Closing Dates; provided,
      however,
      that (i) the aggregate principal amount of the Non-Mandatory Loans shall not
      exceed $1,000,000 without the prior written consent of any two (2) of Essex,
      Care Capital and Galen,(ii) no such Additional Lender may participate without
      the prior written consent of any two (2) of Essex, Care Capital and Galen,
      and
      (iii) no Lender is under any obligation to fund any Loan other than its
      respective Commitment. Upon the funding of any additional Loans (whether
      Mandatory Loans or Non-Mandatory Loans), under this Agreement, the Company
      and
      each Lender and/or Additional Lender making a Loan shall be required to execute
      a Joinder Agreement, which Joinder Agreement shall specify the Commitment of
      such Lender and/or Additional Lender. Any Additional Lender executing a Joinder
      Agreement shall be deemed a “Lender” for all purposes of this Agreement. On the
      date of a Closing (each a “Closing
      Date”),
      the Company shall deliver to each Lender at such Closing a Note, dated the
      applicable Closing Date, in the principal amount equal to such Lender’s
      Commitment or, in the event Galen, Care Capital and/or Essex shall make an
      additional Loan hereunder, the Company shall issue to such Lender an additional
      Note dated the applicable Closing Date in the principal amount equal to such
      Lender’s additional Commitment. The Company shall deliver the foregoing Notes
      against receipt by the Company from each Lender of an amount equal to the
      Commitment of such Lender, in each case by wire transfer in immediately
      available funds in U.S. dollars to an account designated by the Company.
      Notwithstanding anything to the contrary herein, no Lender shall be required
      in
      any circumstances to make Mandatory Loans (x) in an aggregate amount that
      exceeds the aggregate amount of such Lender’s committed amount set forth on
      Schedule 1.3 and Schedule 1.3A, or (y) at any time after the occurrence and
      during the continuance of an Event of Default (including, for such purposes,
      after any event, fact or occurrence that, with the passage of time or giving
      of
      notice, would become an Event of Default) .”;
      and

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    
      	(b)  	
              Each
                of the June 2005 Loan Agreement, the September 2005 Loan Agreement,
                the
                November 2005 Loan Agreement and the January 2006 Loan Agreement
                is
                amended as follows:

            

    

    

    
      	(i)  	
              Section
                2.1 is amended to replace “March 31, 2007” with “September 30, 2007 (or
                such later date as may be agreed to by Lenders holding not less than
                66
                2/3% of the outstanding principal amount of the Loans)”; and
                

            

    

    

    
      	(ii)  	
              Section
                5.12 is hereby deleted in its entirety and replaced with the
                following:

            

    

    

    5.12. ROLLOVER
      RIGHT

     

    Each
      Lender shall have the one-time right (the “Rollover
      Right”)
      on
      the terms provided below, to purchase, through the conversion of all or any
      portion of such Lender’s Notes (including principal and accrued and unpaid
      interest), securities of the Company, on the first to occur of a Third-Party
      Investor Financing, a Conversion Change of Control Transaction or the Maturity
      Date (each a “Material
      Event”)
      after the date hereof, under the terms and conditions set forth in this Section
      5.12. Any portion of such Notes which are not so converted pursuant to this
      Section 5.12 shall become immediately due and payable simultaneously with such
      Material Event. 

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

       

    

    (a)  Simultaneous
      with the completion of an equity financing pursuant to which the Company issues
      its common stock or other equity securities of the Company and, after the
      effectiveness thereof, the Company will have cumulatively received at least
      $5
      million in gross proceeds from equity financings after the date hereof
      (including all equity financings after the date hereof, including such final
      financing which causes the aggregate cumulative proceeds to exceed $5 million,
      but expressly excluding the principal and interest under the Notes for which
      a
      Lender’s Rollover Right is exercised) from unaffiliated, thirty-party investors
      (a “Third-Party Investor Financing”) other than (i) issuances of options or
      restricted stock units to employees, consultants or directors, (ii) interest
      on
      debt payable in common stock or (iii) pursuant to the conversion of warrants,
      options, restricted stock units or other convertible securities outstanding
      on
      the date hereof, each Lender may convert all or any portion (except as provided
      below) of its Notes, at the option of such Lender, under either (but not both
      or
      a combination of each) of the following: 

     

    (i)
      into the same equity securities as are issued in such Third-Party Investor
      Financing on the same terms as provided in such Third-Party Investor Financing
      (but at (A) for all Notes other than the Future Bridge Notes, the average price
      of all equity securities sold that have combined to exceed the cumulative $5
      million in proceeds, and (B) for the Future Bridge Notes, 80% of the average
      price of all equity securities sold that have combined to exceed the cumulative
      $5 million in proceeds), provided that the conversion price per share of Common
      Stock determined pursuant to subsection (A) and (B) shall in no event be less
      than $0.21, or 

     

    (ii)
      (A) for Notes issued in or prior to November 2005 (the “June to November 2005
      Bridge Notes”), convert such Notes into Common Stock at a price of $0.20 per
      share, (B) for Notes issued after November 2005 and in or prior to May 2006
      (the
“January to May 2006 Bridge Notes”), convert such Notes into Common Stock at a
      price of $0.225 per share; (C) for Notes issued after May 2006 and in or prior
      to October 2006 (the “June to October 2006 Bridge Notes”), convert such Notes
      into Common Stock at a price of $0.25 per share; (D)
      for Notes issued or to be issued under the Loan Agreement dated January 31,
      2006
      after October 2006 but prior to March, 2007 (the “November 2006 to February 2007
      Bridge Notes”), convert such Notes into Common Stock at a conversion price equal
      to the lesser of (X) 80% of the average of the closing bid and asked prices
      of
      the Common Stock for the twenty (20) trading days immediately preceding the
      public announcement of the Third-Party Investor Financing, (Y) the average
      price
      of the equity securities sold that have combined to exceed the cumulative $5
      million in proceeds, and (Z) $0.44 per share; provided that the conversion
      price
      per share of Common Stock determined pursuant to subsection (X) and (Y) above
      shall in no event be less than $0.21; provided further that a Lender choosing
      this option must convert all (and not less than all) of its Notes pursuant
      to
      this option; and (E) for other Notes issued or to be issued under the Loan
      Agreement dated January 31, 2006 during March 2007 or thereafter (the “Future
      Bridge Notes”), convert such Notes into Common Stock at a conversion price equal
      to the lesser of (X) 80% of the average of the closing bid and asked prices
      of
      the Common Stock for the twenty (20) trading days immediately preceding the
      public announcement of the Third-Party Investor Financing, (Y) 80% of the
      average price of the equity securities sold that have combined to exceed the
      cumulative $5 million in proceeds, and (Z) $0.46 per share; provided that the
      conversion price per share of Common Stock determined pursuant to subsection
      (X)
      and (Y) above shall in no event be less than $0.21; provided further that a
      Lender choosing this option must convert all (and not less than all) of its
      Notes pursuant to this option.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    (b)  Simultaneous
      with the completion of the first Conversion Change of Control Transaction to
      occur after the date hereof, each Lender may, at the option of such Lender
      convert all (and not less than all) of its Notes as follows, (i) for the June
      to
      November 2005 Bridge Notes, convert such Notes into Common Stock at a price
      of
      $0.20 per share, (ii) for the January to May 2006 Bridge Notes, convert such
      Notes into Common Stock at a price of $0.225 per share; (iii) for the June
      to
      October 2006 Bridge Notes, convert such Notes into Common Stock at a price
      of
      $0.25 per share; and
      (iv) for the November 2006 to February 2007 Bridge Notes and the Future Bridge
      Notes convert such Notes into Common Stock at a price equal to 80% of the value
      per fully diluted share of the Company’s common stock provided in the Conversion
      Change of Control Transaction, but in no event less than $0.21 per share;
      provided, however, that if such Conversion Change of Control Transaction is
      a
      transaction of the type described in subsection (D) or (E) of the definition
      of
      Conversion Change of Control Transaction below, (i) each Lender’s November 2006
      to February 2007 Bridge Notes will be convertible, at the option of such Lender,
      into Common Stock at a price equal to the lesser of (X) 80% of the average
      closing bid and asked prices of the Common Stock for the twenty (20) trading
      days immediately preceding the public announcement of such Conversion Change
      of
      Control Transaction, but in no event less than $0.21 per share; and (Y) $0.44
      per share and (ii) each Lender’s Future Bridge Notes will be convertible, at the
      option of such Lender, into Common Stock at a price equal to the lesser of
      (X)
      80% of the average closing bid and asked prices of the Common Stock for the
      twenty (20) trading days immediately preceding the public announcement of such
      Conversion Change of Control Transaction, but in no event less than $0.21 per
      share; and (Y) $0.46 per share. For purposes hereof, a Conversion Change of
      Control Transaction shall mean any
      of the following in one or a series of related transactions:(A) the acquisition
      (other than solely from the Company) by any individual, entity or group (within
      the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act)
      other than the Company, any Subsidiary, any Lender or its Affiliates or GCE
      Holdings, LLC or its Affiliates, of the beneficial ownership (within the meaning
      of Rule 13d-3 promulgated under the Securities Exchange Act) of more than
      sixty-six and 2/3 percent (66.66%) of the combined voting power of the then
      outstanding voting securities of the Company entitled to vote generally in
      the
      election of directors (the “Voting Securities”); (B) a merger, consolidation,
      share exchange, recapitalization, business combination or similar combination
      involving the Company or its capital stock (a "Business
      Combination"),
      other than a Business Combination in which more than thirty-three and 1/3
      percent (33.33%) of the combined voting power of the outstanding voting
      securities of the surviving or resulting entity immediately following the
      Business Combination is held by the persons who, immediately prior to the
      Business Combination, were the holders of the Voting Securities; (C) a sale
      or
      other transfer (other than license) of all or substantially all of the Company’s
      assets (measured by the value or earning power of the assets); (D) the license
      or similar agreement by the Company to a third party of all or substantially
      all
      rights in and to the Company’s Aversion® technology and, as a result of such
      transaction, all or substantially all of the Company’s activities consist of
      monitoring such arrangements and collecting fees and payments due thereunder;
      or
      (E) a liquidation or dissolution of the Company.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    (c)  At
      the Maturity Date (as the same may be extended pursuant to Section 2.2 hereof)
      each
      Lender may, at the option of such Lender, convert all (and not less than all)
      of
      its Notes as follows, (i) for the June to November 2005 Bridge Notes, convert
      such Notes into Common Stock at a price of $0.20 per share, (ii) for the January
      to May 2006 Bridge Notes, convert such Notes into Common Stock at a price of
      $0.225 per share; (iii) for the June to October 2006 Bridge Notes, convert
      such
      Notes into Common Stock at a price of $0.25 per share; (iv)
      for the November 2006 to February 2007 Bridge Notes convert such Notes into
      Common Stock at the lesser of (X) 80% of the average of the closing bid and
      asked prices of the Common Stock for the twenty (20) trading days immediately
      preceding the Maturity Date, but in no event less than $0.21 per share, and
      (Y)
      $0.44 per share; and (v)
      for the Future Bridge Notes convert such Notes into Common Stock at the lesser
      of (X) 80% of the average of the closing bid and asked prices of the Common
      Stock for the twenty (20) trading days immediately preceding the Maturity Date,
      but in no event less than $0.21 per share, and (Y) $0.46 per
      share.

     

    (d)  The
      Company shall give each Lender written notice (a “Material
      Event Notice”)
      of
      the first Material Event to occur after the date hereof, which notice shall
      be
      provided not later than 20 days prior to the closing of said transaction (or,
      in
      the case of the Maturity Date, the Maturity Date) and describe the material
      terms of such transaction, (or, in the case of the Maturity Date, state the
      Maturity Date), the proposed closing date and the principal amount and interest
      accrued on the Lender’s outstanding Notes.

     

    (e)  Each
      Lender may exercise its Rollover Right with respect to the first Material Event
      to occur after the date hereof by (i) providing written notice to the Company
      exercising such Rollover Right, and (ii) surrendering such Lender’s applicable
      Notes, in each case not later than five (5) days prior to the effectiveness
      of
      the Material Event (the “Rollover
      Right Exercise Period”).
      If the material terms of the actual Material Event differ in any material
      respect from those specified in the Material Event Notice, each Lender shall
      be
      given the opportunity change the conversion election they had made under the
      prior terms (including to elect to convert if they previously did not do
      so).

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    (f)  Upon
      a Lender’s timely exercise of the Rollover Right pursuant to Section 5.12(e)
      above, the issuance of the Company’s equity securities upon conversion of such
      Lender’s Notes in the applicable Material Event shall occur simultaneous with
      the closing of such Material Event (or, in the case of the Maturity Date, on
      the
      Maturity Date). 

     

    (g)  Subject
      to the last sentence of Section 5.12(e), and provided that the Company has
      complied with the terms of this Section 5.12, the Rollover Right provided in
      this Section 5.12 shall apply solely to the first Material Event occurring
      after
      the date hereof, and shall terminate upon the earlier of (i) the expiration
      of
      the Rollover Right Exercise Period (if not exercised by such Lender pursuant
      to
      Section 5.12(e)) and (ii) the closing of the first Material Event (or, in the
      case of the Maturity Date, the Maturity Date) occurring after the date
      hereof.

     

    

    
      	(c)  	
              Each
                of the June 2005 Notes, the September 2005 Notes, the November 2005
                Notes
                and the January 2006 Notes (collectively, the “Notes”) (and each of the
                forms of such Notes attached to the June 2005 Loan Agreement, the
                September 2005 Loan Agreement, the November 2005 Loan Agreement and
                the
                January 2006 Loan Agreement) is amended
                by:

            

    

    
      	(d)  	 

    

    (i)  replacing
      the words March 31, 2007, wherever they appear therein with “September 30, 2007
      (or such later date as may be agreed to by Lenders holding not less than 66
      2/3%
      of the outstanding principal amount of the Loans)”; and

    

    (ii) appending
      the following additional section to such note (to the extent not already
      included therein):

    

    “References
      to Loan Agreement.
      References to the Loan Agreement in this Note shall mean references to the
      Loan
      Agreement, as amended, and as the same may be further amended, supplemented
      or
      modified from time to time.”

    

    
      	(e)  	
              In
                the event a Replacement Note (as hereinafter defined) is issued pursuant
                to Section 4 hereof, then in such Replacement Note the words “Secured
                Promissory Note” shall be replaced with “Amended and Restated Promissory
                Secured Note” and the following section shall be appended thereto:
                

            

    

    

    “Amended
      and Restated Secured Promissory Note.
      This Amended and Restated Secured Promissory Note issued by the Company in
      favor
      of the Payee amends and restates in its entirety, and is issued by the Company
      in replacement of and substitution for a Secured Promissory Note of identical
      principal amount issued to Payee pursuant to the Loan Agreement(the “Original
      Note”). The Company and the Payee acknowledge and agree that upon the execution
      delivery of this Amended and Restated Secured Promissory Note, the Original
      Note
      shall be null and void and of no further legal force or effect.
“

     

    The
      form
      of such Replacement Note shall be also be attached to the applicable Loan
 Agreement
      as an acceptable form of note to be issued pursuant thereto.

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    2. References
      to Loan Documents:
      Any
      reference to any Loan Document in any other Loan Document shall mean the Loan
      Document, as amended hereby. 

    

    

    3.
       Attachment
      to All Notes:
      The
      Lenders covenant to give a copy of this Omnibus Amendment and Consent to any
      purchaser of the June 2005 Notes, the September 2005 Notes, the November 2005
      Notes or the January 2006 Notes prior to the actual purchase and to attach
      a
      copy of this Omnibus Amendment and Consent to any of such notes where the
      undersigned is the named payee or holder.

    

    4. Amended
      and Restated Notes. 
      Upon
      request of the Company, each Lender agrees to deliver to the Company any of
      the
      June 2005 Notes, the September 2005 Notes, the November 2005 Notes or the
      January 2006 Notes issued to them, in exchange for an amended and restated
      Note
      (the “Replacement
      Note”)
      incorporating the amendments set forth in this Omnibus Amendment and Consent.
      

    

    5. Subordination
      Agreement.  Each
      Lender and Additional Watson Holder agrees to the provisions of this Omnibus
      Amendment and Consent, including without limitation, to the amendments to the
      June 2005, September 2005 Notes, the November 2005 Notes and the January 2006
      Notes and acknowledges that the Subordination Agreement shall remain in full
      force and effect .

     

    6.  Notes
      and Agreements Not Assigned. The
      undersigned Lenders and Additional Watson Holders acknowledge that they have
      not
      transferred, conveyed or assigned any of the Watson Note, the June 2005 Notes,
      the September 2005 Notes, the November 2005 Notes or the January 2006 Notes
      issued to them and the undersigned Lenders and Additional Watson Holders
      acknowledge that they have not assigned any rights under the Loan Documents
      or
      under the Subordination Agreement.

    

    7.  Interest
      Payable to Lenders in Stock; Prepayments. Notwithstanding
      anything in the Loan Documents to the contrary (except as set forth in Section
      5.12 thereof), the Company (a) may, at the Company’s option, in full payment of
      all payments of interest on the Notes to the undersigned Lenders  (“Interest
      Due”)
      make
      payment of the Interest Due in such number of shares of Common Stock of the
      Company equal to the quotient of the Interest Due such Lender, divided by the
      average of the closing bid and asked price of the Company’s Common Stock for the
      five (5) trading days immediately preceding the due date of such Interest Due,
      as reported by the Nasdaq OTCBB, and (b) may not prepay the principal amount
      of
      any Note, or any interest thereon, in whole or in part, at any time without
      the
      prior written consent of the holder thereof. 

    

    8.
       Counterparts:
      This
      Omnibus Amendment and Consent may be executed in one or more counterparts and
      by
      different parties hereto in separate counterparts, including by facsimile,
      each
      of which when so executed and delivered shall be deemed an original, but all
      such counterparts together shall constitute but one and the same instrument.
      

    

    

    9.
       Governing
      Law:
      THIS
      OMNIBUS AMENDMENT AND CONSENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES
      HEREUNDER SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF
      THE
      STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF
      LAWS.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF, each of the Parties have caused this Omnibus Amendment and
      Consent to be duly executed and delivered as of the day and year first above
      written.

     

    
      	 	 	 
	 	ACURA
              PHARMACEUTICALS, INC.
	 
 	 
 	 
 
	 	By:  	/s/ Peter
              A.
              Clemens
	 	
              
Name:
              Peter A. Clemens
	 	Title:
              Sr. Vice President and CFO

      	 	 	 
	 	
              ACURA
                PHARMACEUTICAL

              TECHNOLOGIES
                , INC.

            
	 
 	 
 	 
 
	 	By:  	/s/ Peter
              A.
              Clemens
	 	
              
Name:
              Peter A. Clemens
	 	Title:
              Sr. Vice President and CFO

    

     

    
      	
              LENDER
                AND AGENT:

              GALEN
                PARTNERS III, L.P.

              By:
                Claudius, L.L.C., General Partner

              610
                Fifth Avenue, 5th
                Fl.

              New
                York, New York 10019

               

               
                /s/ Bruce
                Wesson                                         
                

              By:
                Bruce Wesson

              Its:
                General Partner

            	
              LENDER:

              CARE
                CAPITAL OFFSHORE INVESTMENTS II, LP

              By:
                Care Capital II, LLC, as general partner

              47
                Hulfish Street, Suite 310

              Princeton,
                NJ 08542

               

              By:
                 /s/
                David
                Ramsay                                    
                

              By:
                David R. Ramsay

              Its:
                Authorized Signatory

            
	 	 
	
              LENDER:

              GALEN
                PARTNERS INTERNATIONAL, III, L.P.

              By:
                Claudius, L.L.C., General Partner

              610
                Fifth Avenue, 5th
                Floor

              New
                York, New York 10020

               

               
                /s/ Bruce
                Wesson                                           
                

              By:
                Bruce Wesson

              Its:
                General Partner 

            	
              LENDER:

              CARE
                CAPITAL INVESTMENTS II, LP

              By:
                Care Capital II, LLC, as general partner

              47
                Hulfish St., Suite 310

              Princeton,
                NJ 08542

               

              By:
                 /s/
                David
                Ramsay                                       
                

              Name:
                David R. Ramsay

              Title:
                Authorized Signatory

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              LENDER:

              GALEN
                EMPLOYEE FUND III, L.P.

              By:
                Wesson Enterprises, Inc.

              610
                Fifth Avenue, 5th
                Floor

              New
                York, New York 10020

               

               

               
                /s/ Bruce
                Wesson                                        
                

              By:
                Bruce F. Wesson

              Its:
                General Partner

            	
              LENDER:

              ESSEX
                WOODLANDS HEALTH 

              VENTURES
                V, L.P.

              190
                South LaSalle Street, Suite 2800

              Chicago,
                IL 60603

               

               

               
                /s/ Immanuel
                Thangaraj                                   
                

              By:
                Immanuel Thangaraj

              Its:
                Managing Director

            

    

    
      	 	 
	
              LENDER:

              MICHAEL
                WEISBROT

              1136
                Rock Creek Road

              Gladwyne,
                Pennsylvania 19035

               

               

               
                /s/ Michael
                Weisbrot                                   
                

            	
              LENDER:

              SUSAN
                WEISBROT

              1136
                Rock Creek Road

              Gladwyne,
                Pennsylvania 19035

               

               

               
                /s/ Susan
                Weisbrot                                          
                

               

            
	
              LENDER:

              DENNIS
                ADAMS

              120
                Kynlyn Road

              Radnor,
                Pennsylvania 19312

               

               
                /s/ Dennis
                Adams                                        
                

            	
              LENDER:

              GEORGE
                E. BOUDREAU

              222
                Elbow Lane

              Haverford,
                PA 19041

               

               
                /s/ George
                Boudreau                                       
                

            
	 	 
	
              ADDITIONAL
                WATSON HOLDER:

              PETER
                STIEGLITZ

              RJ
                Palmer LLC

              156
                West 56th Street, 5th Floor

              New
                York, New York 10019

               

               
                /s/ Peter
                Stieglitz                                            
                

            	
              ADDITIONAL
                WATSON HOLDER:

              JOHN
                E. HEPPE, JR. 

              237
                W. Montgomery Avenue

              Haverford,
                Pennsylvania 19041

               

               

               
                /s/ John
                Heppe                                                  
                

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    Schedule
      1.3

    Funding
      Schedule of $ 2,000,000 in Bridge Loans

    All
      Amounts Under This Schedule Have Already Been Funded

     

    

      
        	
                 

              	 	
                Month

              	 	
                 

              	 	
                 

              	 
	 	 	
                Commitment
                  to

              	 	
                
                  Commitment

                

              	 	
                
                  Percentage
                    of

                

              	 
	
                Lender
                  Name

              	 	
                be
                  Funded

              	 	
                 Amount

              	 	
                 Commitment

              	 
	
                GALEN
                  PARTNERS III, L.P.

              	 	 	
                November
                  2006

              	 	
                $

              	
                203,014.61

              	 	 	
                30.452191

              	
                %

              
	
                GALEN
                  PARTNERS INTERNATIONAL, III,
                  L.P.

              	 	 	 	 	
                $

              	
                18,376.31

              	 	 	
                2.756447

              	
                %

              
	
                GALEN
                  EMPLOYEE FUND III, L.P.

              	 	 	 	 	
                $

              	
                831.31

              	 	 	
                0.124696

              	
                %

              
	
                ESSEX
                  WOODLANDS HEALTH VENTURES
                  V, L.P.

              	 	 	 	 	
                $

              	
                222,222.20

              	 	 	
                33.33333

              	
                %

              
	
                CARE
                  CAPITAL INVESTMENTS II, LP

              	 	 	 	 	
                $

              	
                207,955.53

              	 	 	
                31.19333

              	
                %

              
	
                CARE
                  CAPITAL OFFSHORE INVESTMENTS
                  II, LP

              	 	 	 	 	
                $

              	
                14,266.67

              	 	 	
                2.14000

              	
                %

              
	
                TOTAL
                  FOR NOVEMBER 2006

              	 	 	 	 	
                $

              	
                666,666.67

              	 	 	 	 
	
                GALEN
                  PARTNERS III, L.P.

              	 	 	
                December
                  2006

              	 	
                $

              	
                203,014.61

              	 	 	
                30.452191

              	
                %

              
	
                GALEN
                  PARTNERS INTERNATIONAL, III,
                  L.P.

              	 	 	 	 	
                $

              	
                18,376.31

              	 	 	
                2.756447

              	
                %

              
	
                GALEN
                  EMPLOYEE FUND III, L.P.

              	 	 	 	 	
                $

              	
                831.31

              	 	 	
                0.124696

              	
                %

              
	
                ESSEX
                  WOODLANDS HEALTH VENTURES
                  V, L.P.

              	 	 	 	 	
                $

              	
                222,222.20

              	 	 	
                33.33333

              	
                %

              
	
                CARE
                  CAPITAL INVESTMENTS II, LP

              	 	 	 	 	
                $

              	
                207,955.53

              	 	 	
                31.19333

              	
                %

              
	
                CARE
                  CAPITAL OFFSHORE INVESTMENTS
                  II, LP

              	 	 	 	 	
                $

              	
                14,266.67

              	 	 	
                2.14000

              	
                %

              
	
                TOTAL
                  FOR DECEMBER 2006

              	 	 	 	 	
                $

              	
                666,666.67

              	 	 	 	 
	
                GALEN
                  PARTNERS III, L.P.

              	 	 	
                January
                  2007

              	 	
                $

              	
                203,014.61

              	 	 	
                30.452191

              	
                %

              
	
                GALEN
                  PARTNERS INTERNATIONAL, III,
                  L.P.

              	 	 	 	 	
                $

              	
                18,376.31

              	 	 	
                2.756447

              	
                %

              
	
                GALEN
                  EMPLOYEE FUND III, L.P.

              	 	 	 	 	
                $

              	
                831.31

              	 	 	
                0.124696

              	
                %

              
	
                ESSEX
                  WOODLANDS HEALTH VENTURES
                  V, L.P.

              	 	 	 	 	
                $

              	
                222,222.20

              	 	 	
                33.33333

              	
                %

              
	
                CARE
                  CAPITAL INVESTMENTS II, LP

              	 	 	 	 	
                $

              	
                207,955.53

              	 	 	
                31.19333

              	
                %

              
	
                CARE
                  CAPITAL OFFSHORE INVESTMENTS
                  II, LP

              	 	 	 	 	
                $

              	
                14,266.67

              	 	 	
                2.14000

              	
                %

              
	
                TOTAL
                  FOR JANUARY 2007

              	 	 	 	 	
                $

              	
                666,666.67

              	 	 	 	 

      

    

    
      
         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Schedule
      1.3A

    Funding
      Schedule of $ 1,200,000 in Bridge Loans

     

    

      
        	
                 

              	 	
                Month

              	 	
                 

              	 	
                 

              	 
	 	 	
                Commitment
                  to

              	
                 

              	
                Commitment

              	
                 

              	
                
                  Percentage
                    of

                

              	 
	
                Lender
                  Name

              	
                 

              	
                be
                  Funded

              	
                 

              	
                Amount

              	 	
                Commitment

              	 
	
                GALEN
                  PARTNERS III, L.P.

              	 	 	
                March
                  2007

              	 	
                $

              	
                182,713.15

              	 	 	
                30.452191

              	
                %

              
	
                GALEN
                  PARTNERS INTERNATIONAL, III,
                  L.P.

              	 	 	 	 	
                $

              	
                16,538.68

              	 	 	
                2.756447

              	
                %

              
	
                GALEN
                  EMPLOYEE FUND III, L.P.

              	 	 	 	 	
                $

              	
                748.18

              	 	 	
                0.124696

              	
                %

              
	
                ESSEX
                  WOODLANDS HEALTH VENTURES
                  V, L.P.

              	 	 	 	 	
                $

              	
                199,999.98

              	 	 	
                33.33333

              	
                %

              
	
                CARE
                  CAPITAL INVESTMENTS II, LP

              	 	 	 	 	
                $

              	
                187,159.98

              	 	 	
                31.19333

              	
                %

              
	
                CARE
                  CAPITAL OFFSHORE INVESTMENTS
                  II, LP

              	 	 	 	 	
                $

              	
                12,840.00

              	 	 	
                2.14000

              	
                %

              
	
                TOTAL
                  FOR March 2007

              	 	 	 	 	
                $

              	
                600,000

              	 	 	 	 
	
                GALEN
                  PARTNERS III, L.P.

              	 	 	
                April
                  2007

              	 	
                $

              	
                91,356.57

              	 	 	
                30.452191

              	
                %

              
	
                GALEN
                  PARTNERS INTERNATIONAL, III, L.P

              	 	 	 	 	
                $

              	
                8,269.34

              	 	 	
                2.756447

              	
                %

              
	
                GALEN
                  EMPLOYEE FUND III, L.P.

              	 	 	 	 	
                $

              	
                374.09

              	 	 	
                0.124696

              	
                %

              
	
                ESSEX
                  WOODLANDS HEALTH VENTURES
                  V, L.P.

              	 	 	 	 	
                $

              	
                99,999.99

              	 	 	
                33.33333

              	
                %

              
	
                CARE
                  CAPITAL INVESTMENTS II, LP

              	 	 	 	 	
                $

              	
                93,579.99

              	 	 	
                31.19333

              	
                %

              
	
                CARE
                  CAPITAL OFFSHORE INVESTMENTS
                  II, LP

              	 	 	 	 	
                $

              	
                6,420.00

              	 	 	
                2.14000

              	
                %

              
	
                TOTAL
                  FOR April 2007

              	 	 	 	 	
                $

              	
                300,000

              	 	 	 	 
	
                GALEN
                  PARTNERS III, L.P.

              	 	 	
                May
                  2007

              	 	
                $

              	
                91,356.57

              	 	 	
                30.452191

              	
                %

              
	
                GALEN
                  PARTNERS INTERNATIONAL, III,
                  L.P.

              	 	 	 	 	
                $

              	
                8,269.34

              	 	 	
                2.756447

              	
                %

              
	
                GALEN
                  EMPLOYEE FUND III, L.P.

              	 	 	 	 	
                $

              	
                374.09

              	 	 	
                0.124696

              	
                %

              
	
                ESSEX
                  WOODLANDS HEALTH VENTURES
                  V, L.P.

              	 	 	 	 	
                $

              	
                99,999.99

              	 	 	
                33.33333

              	
                %

              
	
                CARE
                  CAPITAL INVESTMENTS II, LP

              	 	 	 	 	
                $

              	
                93,579.99

              	 	 	
                31.19333

              	
                %

              
	
                CARE
                  CAPITAL OFFSHORE INVESTMENTS
                  II, LP

              	 	 	 	 	
                $

              	
                6,420.00

              	 	 	
                2.14000

              	
                %

              
	
                TOTAL
                  FOR May 2007

              	 	 	 	 	
                $

              	
                300,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]